Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 37 articles:
HTML format
Text format



Single Articles


    October 2017
  1. MCWILLIAMS RR, Allred JB, Slostad JA, Katipamula R, et al
    NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab +/- everolimus for metastatic melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31072.
    PubMed     Text format     Abstract available


  2. AMIT M, Tam S, Abdelmeguid AS, Roberts DB, et al
    Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31083.
    PubMed     Text format     Abstract available


  3. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Cancer. 2017 Oct 12. doi: 10.1002/cncr.30946.
    PubMed     Text format     Abstract available


    August 2017
  4. ROBIN TP, Jones BL, Gordon OM, Phan A, et al
    A comprehensive comparative analysis of treatment modalities for sinonasal malignancies.
    Cancer. 2017;123:3040-3049.
    PubMed     Text format     Abstract available


    June 2017
  5. SZCZEPANIAK SLOANE RA, Gopalakrishnan V, Reddy SM, Zhang X, et al
    Interaction of molecular alterations with immune response in melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  6. BYRNE EH, Fisher DE
    Immune and molecular correlates in melanoma treated with immune checkpoint blockade.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  7. WESTPHAL D, Glitza Oliva IC, Niessner H
    Molecular insights into melanoma brain metastases.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  8. LIM SY, Menzies AM, Rizos H
    Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  9. PEREZ-GUIJARRO E, Day CP, Merlino G, Zaidi MR, et al
    Genetically engineered mouse models of melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  10. REDDY BY, Miller DM, Tsao H
    Somatic driver mutations in melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  11. BARUCH EN, Berg AL, Besser MJ, Schachter J, et al
    Adoptive T cell therapy: An overview of obstacles and opportunities.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  12. JOHNSON DB, Sullivan RJ, Menzies AM
    Immune checkpoint inhibitors in challenging populations.
    Cancer. 2017;123:1904-1911.
    PubMed     Text format     Abstract available


    May 2017
  13. SHIELD PW, Frost F, Finnimore JL, Wright RG, et al
    External quality assurance in nongynecologic cytology: The Australasian experience.
    Cancer. 2017;125:349-361.
    PubMed     Text format     Abstract available


    March 2017
  14. KALINSKY K, Lee S, Rubin KM, Lawrence DP, et al
    A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30663.
    PubMed     Text format     Abstract available


    February 2017

  15. Some Europeans with melanoma lack access to new, lifesaving drugs.
    Cancer. 2017;123:543-544.
    PubMed     Text format    


    December 2016
  16. HOU JY, Baptiste C, Hombalegowda RB, Tergas AI, et al
    Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30473.
    PubMed     Text format     Abstract available


  17. KIM DW, Haydu LE, Joon AY, Bassett RL Jr, et al
    Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.
    Cancer. 2016 Dec 2. doi: 10.1002/cncr.30463.
    PubMed     Text format     Abstract available


    October 2016
  18. CLARKE LE, Flake DD 2nd, Busam K, Cockerell C, et al
    An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.
    Cancer. 2016 Oct 21. doi: 10.1002/cncr.30385.
    PubMed     Text format     Abstract available


    August 2016
  19. BHATIA S, Margolin K
    Disparate clinical activity of PD-1 blockade in melanoma subtypes: Know thy enemy!
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30260.
    PubMed     Text format    


  20. SHOUSHTARI AN, Munhoz RR, Kuk D, Ott PA, et al
    The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30259.
    PubMed     Text format     Abstract available


  21. ALGAZI AP, Tsai KK, Shoushtari AN, Munhoz RR, et al
    Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-1L antibodies.
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30258.
    PubMed     Text format     Abstract available


  22. JHAWAR SR, Kaufman HL, Goyal S
    Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Cancer. 2016 Aug 6. doi: 10.1002/cncr.30244.
    PubMed     Text format    


  23. YU JB, Chiang VL
    Reply to timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Cancer. 2016 Aug 6. doi: 10.1002/cncr.30243.
    PubMed     Text format    


    July 2016
  24. CURIEL-LEWANDROWSKI C, Swetter SM
    Lack of harms from community-based melanoma screening by primary care providers.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30194.
    PubMed     Text format    


  25. WEINSTOCK MA, Ferris LK, Saul MI, Geller AC, et al
    Downstream consequences of melanoma screening in a community practice setting: First results.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30177.
    PubMed     Text format     Abstract available


    June 2016
  26. QIAN JM, Yu JB, Kluger HM, Chiang VL, et al
    Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Cancer. 2016 Jun 10. doi: 10.1002/cncr.30138.
    PubMed     Text format     Abstract available


    April 2016
  27. PRINTZ C
    FDA approves new treatment of metastatic melanoma.
    Cancer. 2016;122:1149.
    PubMed     Text format    


    March 2016
  28. CHATTOPADHYAY C, Kim DW, Gombos DS, Oba J, et al
    Uveal melanoma: From diagnosis to treatment and the science in between.
    Cancer. 2016 Mar 15. doi: 10.1002/cncr.29727.
    PubMed     Text format     Abstract available


    February 2016
  29. TRICOLI JV, Blair DG, Anders CK, Bleyer A, et al
    Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.
    Cancer. 2016 Feb 5. doi: 10.1002/cncr.29871.
    PubMed     Text format     Abstract available


    October 2015
  30. STANG A, Jockel KH
    Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany.
    Cancer. 2015 Oct 19. doi: 10.1002/cncr.29755.
    PubMed     Text format     Abstract available


    August 2015
  31. WEISS SA, Hanniford D, Hernando E, Osman I, et al
    Revisiting determinants of prognosis in cutaneous melanoma.
    Cancer. 2015 Aug 26. doi: 10.1002/cncr.29634.
    PubMed     Text format     Abstract available


  32. BUCHBINDER EI, Sosman JA, Lawrence DP, McDermott DF, et al
    Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
    Cancer. 2015 Aug 11. doi: 10.1002/cncr.29622.
    PubMed     Text format     Abstract available


    July 2015
  33. MENZIES AM, Wilmott JS, Drummond M, Lo S, et al
    Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Cancer. 2015 Jul 28. doi: 10.1002/cncr.29586.
    PubMed     Text format     Abstract available


    June 2015
  34. PRINTZ C
    Coffee may lower risk of malignant melanoma.
    Cancer. 2015;121:1913.
    PubMed     Text format    


  35. LEHRER S
    Finasteride and dutasteride may reduce melanoma risk.
    Cancer. 2015 Jun 8. doi: 10.1002/cncr.29520.
    PubMed     Text format    


  36. LI WQ, Han J
    Reply to finasteride and dutasteride may reduce melanoma risk.
    Cancer. 2015 Jun 8. doi: 10.1002/cncr.29519.
    PubMed     Text format    


    May 2015
  37. ZHANG M, Qureshi AA, Fortner RT, Hankinson SE, et al
    Teenage acne and cancer risk in US women: A prospective cohort study.
    Cancer. 2015;121:1681-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: